Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy
Jordan Gauthier(Seattle Cancer Care Alliance), Cameron J. Turtle(The University of Sydney), David G. Maloney(Fred Hutch Cancer Center), Aiko Torkelson(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Delaney Kirchmeier(Fred Hutch Cancer Center), Christina Poh(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Carla A. Jaeger-Ruckstuhl(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ryan D. Cassaday(University of Washington), Stanley R. Riddell(Fred Hutch Cancer Center), Abigail Chutnik(Fred Hutch Cancer Center), Jennifer J. Huang(Stanford Medicine), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barbara Pender(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k